Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Nonsense-mediated mRNA Decay02:27

Nonsense-mediated mRNA Decay

The Upf proteins that carry out nonsense-mediated decay (NMD) are found in all eukaryotic organisms, including humans. Each protein has an individual role, but they need to work in collaboration. Upf1 is an ATP-dependent RNA helicase that unwinds the RNA helix. Because Upf1 can unwind any RNA, Upf2 and Upf3 are required to help Upf1 discriminate between nonsense and normal mRNAs.
Usually, Upf3 binds to an Exon Junction Complex (EJC) at mRNA splice sites. If a ribosome fully translates the mRNA,...
Alternative RNA Splicing02:18

Alternative RNA Splicing

Alternative RNA splicing is the regulated splicing of exons and introns to produce different mature mRNAs from a single pre-mRNA. Unlike in constitutive splicing where a single gene produces a single type of mRNA, alternative splicing allows an organism to produce multiple proteins from a single gene and plays an important role in protein diversity.
There are five types of alternative RNA splicing that vary in the ways the pre-mRNA segments are removed or retained in the mature mRNA. The first...
Satellite Stem Cells and Muscular Dystrophy01:21

Satellite Stem Cells and Muscular Dystrophy

Satellite stem cells or myosatellite cells are quiescent stem cells that Alexander Mauro first identified in 1961. These cells are located between the sarcolemma, the plasma membrane of muscle fibers, and the basal lamina, the connective tissue sheath covering it. These mononucleated cells are activated in response to muscle injury, can transform into myoblasts, and may form or repair muscle fibers. Myosatellite cells can provide additional myonuclei for muscle regeneration or return to a...

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Defining Haplosufficiency in Autosomal Recessive Limb-Girdle Muscular Dystrophy Using Molecular Markers in Disease Carriers.

Neurology. Genetics·2026
Same author

Tissue-specific CTG•CAG expansion rate and disease severity are modified by DNA repair genes expression levels in myotonic dystrophy type 1 patients.

DNA repair·2026
Same author

A simple, sensitive microsample LC-MS assay for quercetin and isorhamnetin in mouse and human plasma: application to EMIQ treatment in myotonic dystrophy type 1.

Bioanalysis·2026
Same author

A new era for myotonic dystrophy: Improved delivery of a DMPK-targeted oligonucleotide modulates muscle transcriptomes and function.

Molecular therapy : the journal of the American Society of Gene Therapy·2026
Same author

Assessment of scoring functions for computational models of protein-protein interfaces.

Physical review. E·2026
Same author

Loss of the endoplasmic reticulum protein canopy 1 disrupts the function and circuit organization of V2R-expressing vomeronasal sensory neurons.

Development (Cambridge, England)·2026

相关实验视频

Updated: May 11, 2026

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

修改过的多环化合物在肌性发育不良1型疾病模型中拯救错误拼接.

Jesus A Frias1,2, Sawyer M Hicks1,2, Hormoz Mazdiyasni1

  • 1The RNA Institute, College of Arts and Sciences, University at Albany, State University of New York, Albany, New York 12222, United States.

ACS chemical biology
|February 20, 2026
PubMed
概括

新的修饰多环化合物 (MPC) 显示出治疗1型肌性缩症 (DM1) 的前景. 这些化合物拯救了拼接缺陷,并在DM1模型中减少有毒RNA,具有最小的毒性,提供了潜在的治疗途径.

更多相关视频

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

相关实验视频

Last Updated: May 11, 2026

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy
10:30

Multi-exon Skipping Using Cocktail Antisense Oligonucleotides in the Canine X-linked Muscular Dystrophy

Published on: May 24, 2016

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells
09:39

Modeling Myotonic Dystrophy 1 in C2C12 Myoblast Cells

Published on: July 29, 2016

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders
10:28

Direct Reprogramming of Human Fibroblasts into Myoblasts to Investigate Therapies for Neuromuscular Disorders

Published on: April 3, 2021

科学领域:

  • 生物化学 生物化学
  • 遗传学 是一个遗传学.
  • 药理学 药理学是指药理学的学科.

背景情况:

  • 肌性缩症1型 (DM1) 是一种严重的遗传疾病,没有针对性的治疗方法.
  • DM1的发病包括扩展的CUG重复RNA (CUGexp) 隔离MBNL蛋白质,导致拼接错误.

研究的目的:

  • 开发用于DM1的新疗法.
  • 为了确定可以挽救DM1相关拼接缺陷的化合物.

主要方法:

  • 在DM1患者衍生的细胞系中选改性多环化合物 (MPC).
  • 在DM1小鼠模型中测试化合物 (MPC03,MPC04).
  • RNA结合测试和计算建模以阐明作用机制.

主要成果:

  • MPC03和MPC04在低纳米分子度下挽救了DM1拼接缺陷,没有观察到毒性.
  • 在体内治疗降低了CUGexpRNA水平,并在DM1小鼠模型中部分纠正了错误拼接.
  • MPCs与CUGexpRNA结合,取代MBNL蛋白,恢复正常的拼接.

结论:

  • 改性多环化合物 (MPC) 是DM1.1治疗的有前途的新疗法.
  • 通过与CUGexpRNA相互作用,MPCs有效地向疾病机制.
  • 这些化合物在DM1.1的细胞和动物模型中显示出治疗潜力.